Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab

[1]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[2]  S. Loibl,et al.  Management of venous port systems in oncology: a review of current evidence. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Sargent,et al.  3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) , 2007 .

[5]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[6]  W. Scheithauer,et al.  Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer , 2007 .

[7]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  C. Porta,et al.  Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  K. Barnard.  Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? , 2006, Circulation.

[11]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[14]  D. Anderson,et al.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Barbui,et al.  Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study , 2005, British journal of haematology.

[18]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. P. Reed,et al.  Hickman catheters in association with intensive cancer chemotherapy , 1993, Supportive Care in Cancer.

[21]  G. Agnelli,et al.  Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ylä-Herttuala,et al.  Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[25]  R. Gamelli,et al.  Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. , 1998, The American journal of pathology.

[26]  I. Erden,et al.  The risk factors in central venous catheter-related thrombosis. , 1995, The Australian and New Zealand journal of surgery.

[27]  M. Monreal,et al.  Pulmonary Embolism in Patients with Upper Extremity DVT Associated to Venous Central Lines - A Prospective Study , 1994, Thrombosis and Haemostasis.

[28]  J. Bertrand,et al.  Low molecular weight heparin for hickman catheter‐induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation , 1993, Cancer.

[29]  J. Lokich,et al.  Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy , 1983, Cancer.